ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Condition(s) studied

Investigational drug(s) / intervention(s)

Efgartigimod IV: Intravenous infusion of efgartigimod

Empasiprubart IV: Intravenous infusion of empasiprubart

Placebo IV: Intravenous infusion of placebo

Efgartigimod PH20 SC PFS: Subcutaneous administration of Efgartigimod PH20 via pre-filled syringe (PFS)

Study summary

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Eligibility

Primary outcome measure(s)

• To determine the safety and tolerability of multiple regimens (monotherapy or add-on therapy to backbone therapy) in MG subtypes — Up to approximately 7 years (the duration of each ISA will vary and be specified on the ISA records)

Trial sites (30)